Jane Street’s Regencell Bioscience RGC Stock Holding History

Jane Street’s Portfolio RGC Stock Details RGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,400	Closed	-$176K	–	12170
2025 Q3	$176K	Buy	+11,400	New	+$164K	﹤0.01%	9769

Other funds holding RGC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Jane Street's RGC Position: Q4 2025 in Review

Jane Street sold out of Regencell Bioscience (RGC) in Q4 2025, closing a stake of 10,616 shares — an estimated $173K sold.

Jane Street first reported a position in RGC in Q3 2025 and held it in 1 quarter. The position peaked at $164K in Q3 2025. 17 funds tracked by Wall St. Rank hold RGC as of Q4 2025.

Jane Street reported no remaining Regencell Bioscience position as of Q4 2025 after selling out during the quarter.
Jane Street sold 10,616 Regencell Bioscience shares in Q4 2025, an estimated $173K.
Jane Street first reported a position in Regencell Bioscience in Q3 2025 and held it in 1 quarter.
Jane Street's Regencell Bioscience position peaked at $164K in Q3 2025.
17 funds tracked by Wall St. Rank held Regencell Bioscience as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.